PCVX logo

VAXCYTE INC

PCVXNASDAQ
🏆 #980 by market capUS Equity
$527.30▲ $13.82 (+2.62%)
Simulated price
🔔
Track PCVX
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 2.6%
7d▲ 792.8%
14d▲ 790.6%
30d▲ 781.0%
ytd▲ 1043.8%
1y▲ 1420.5%
🏦Market Cap
$8.41B
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
60
Fair

Trading Snapshot

Day Range
$520.45 – $532.44
52-Week Range
$33.62 – $65.00
Volume
$2.71B
Avg Volume
$3.22B
Shares Outstanding
144.4M
Next Earnings
Oct 31, 2026

Fundamentals Snapshot

Annual Revenue
$801M
Last Q Revenue
$209M
P/E Ratio
-7.6
P/S Ratio
0.0x
EPS (TTM)
$-7.37
Dividend Yield
0.00%
Dilution (1yr)
+10.8%

Why Investors Own PCVX

  • ✓High-growth profile — revenue up +52.6% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 70% gross margin and 19% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

PCVX logo

VAXCYTE INC

PCVX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$924M▲ +62.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$669M▲ +40.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
136.1M▲ +10.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$55M▼ −$372M YoY
StockOtter · stockotter.space

About VAXCYTE INC

Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Price Target

ⓘ
Average Target
$611.07
▲ +15.9% Upside
High Target$747.20
Low Target$452.94
Based on 14 analysts

Latest News & Updates

🚀
Barron’s·2h ago

VAXCYTE INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift PCVX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

VAXCYTE INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.